Received Mar 23, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 1 | Unknown | PO / MO |
Diverticulosis; Infection; The patient took the first dose of Vivotif on 02-Aug-2024 and and then the doctor advised patient to stop Vivotif; Case reference number US-BN-2024-002354 is a spontaneous case initially received from a pharmacist via agency (reference number USBAV24-2004) on 16-Aug-2024 and concerns a female patient of about 70-years-old. The patient's medical history and concomitant medication details were not provided. On 02-Aug-2024, reported as at night, the patient took the first dose of Vivotif (batch number: unknown), at a dose of pill, orally, for typhoid immunization. On unspecified date, reported as the next day, the patient presented diverticulosis and had an infection, so the doctor advised patient to stop Vivotif while taking Augmentin (amoxicillin) prescribed for the infection (explicitly coded as 'inappropriate schedule of vaccine administered'). As reported, the patient finished a ten-day course of antibiotic. At the time of initial report, it was unknown if the patient recovered from events of diverticulosis and infection. The reporter assessed the events of diverticulitis and infection as non-serious and possibly related to the Vivotif. Non-significant follow-up was downloaded from VAERS on 09-May-2025 included new reference number. Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20240816-fbbac4 to US-BAVARIAN NORDIC A/S-US-BN-2024-002354, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: A 70 years old female patient experienced diverticulosis and had an infection, one day after she took the first dose of Vivotif, at a dose of pill, for typhoid immunization. Reportedly, the doctor advised patient to stop Vivotif while taking Augmentin (amoxicillin) which was prescribed for the infection and that is considered as inappropriate schedule of vaccine administered. Diverticulum and infection are unlisted and unexpected according to CCDS v8 and USPI while inappropriate schedule of product administration is considered listed per company convention. The outcome of diverticulum and infection was unknown. Causal relationship for diverticulum and infection was assessed as related due to plausible temporal relationship and since contributory role of suspect product cannot be excluded. Inappropriate schedule of product administration is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A 70 years old female patient experienced diverticulosis and had an infection, one day after she took the first dose of Vivotif, at a dose of pill, for typhoid immunization. Reportedly, the doctor advised patient to stop Vivotif while taking Augmentin (amoxicillin) which was prescribed for the infection and that is considered as inappropriate schedule of vaccine administered. Diverticulum and infection are unlisted and unexpected according to CCDS v8 and USPI while inappropriate schedule of product administration is considered listed per company convention. The outcome of diverticulum and infection was unknown. Causal relationship for diverticulum and infection was assessed as related due to plausible temporal relationship and since contributory role of suspect product cannot be excluded. Inappropriate schedule of product administration is assessed as not related to suspect product but to human factor. The case is non-serious. USBAV24-2004:
Comments: NONE